Clinical Trial Search

Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants

Primary: Functional Walk Test — 498.4; 503.2; 564.2 meters — p==0.06

Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants

Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants

Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted

Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF

Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015

Primary: Effectiveness: Without-fail Care Rate — 95; 363 Participants

Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28

Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067

Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants

Primary: Number of Participants With Composite of Stroke/MI/Death — 442; 497 Participants — p=0.0670

Primary: Blood Pressure and Heart Rates;

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Blood Pressure Variability — 0.106; 0.107 coefficient of variation

Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: the Rate of Patients With a Modified Rankin Scale Score of 0-1 — 109; 98; 46; 39 participants

Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >

Primary: All-cause Mortality at 1 Year (Percentage of Patients With Modified Rankin Scale (mRS) Score =6) — 11.1; 12.2 Percentage of Participants — p=0.183

Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086

Primary: Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR]) — 2.17; 2.37 mL — p=0.779

Primary: HOMA IR Change From Baseline — 0.9; 4.0; 4.1 HOMA-IR Index

Primary: Number of Subjects With Positive T Wave Studies During a Coronary Intervention — 0 participants